Modulation of immune responses with transcutaneously deliverable adjuvants
- PMID: 15193399
- DOI: 10.1016/j.vaccine.2003.11.063
Modulation of immune responses with transcutaneously deliverable adjuvants
Abstract
Transcutaneous immunisation is a novel vaccination strategy based on the application of antigen together with an adjuvant onto hydrated bare skin. This simple and non-invasive immunisation procedure elicits systemic and mucosal immune responses and therefore, it provides a viable and cost-effective strategy for disease prevention. For the induction of antigen-specific immune responses the use of adjuvants is critical. They potentiate and modulate the type of immune responses by stimulating the production of cytokines that drive the differentiation of T cells towards the Th1 or Th2-phenotype. These cells mediate protection against different infectious diseases and therefore, their selective induction is important for successful vaccination. In this review we give a brief overview of transcutaneously deliverable adjuvants and we discuss how they modulate immune responses to topically applied antigens.
Similar articles
-
ISCOMATRIX adjuvant: a potent inducer of humoral and cellular immune responses.Vaccine. 2004 Jun 23;22(19):2391-5. doi: 10.1016/j.vaccine.2003.12.031. Vaccine. 2004. PMID: 15193400 Review.
-
Development of novel fusogenic vesosomes for transcutaneous immunization.Vaccine. 2006 Jul 7;24(27-28):5559-70. doi: 10.1016/j.vaccine.2006.04.030. Epub 2006 May 4. Vaccine. 2006. PMID: 16730102
-
Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.Vaccine. 2008 Mar 4;26(10):1375-86. doi: 10.1016/j.vaccine.2007.12.038. Epub 2008 Jan 14. Vaccine. 2008. PMID: 18272264 Clinical Trial.
-
Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.Immunol Lett. 2005 Mar 15;97(2):181-8. doi: 10.1016/j.imlet.2004.11.009. Epub 2004 Dec 7. Immunol Lett. 2005. PMID: 15752556 Review.
-
Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults.Vaccine. 2005 Apr 8;23(20):2591-601. doi: 10.1016/j.vaccine.2004.11.034. Vaccine. 2005. PMID: 15780441 Clinical Trial.
Cited by
-
Transcutaneous immunization with cross-reacting material CRM(197) of diphtheria toxin boosts functional antibody levels in mice primed parenterally with adsorbed diphtheria toxoid vaccine.Infect Immun. 2008 Apr;76(4):1766-73. doi: 10.1128/IAI.00797-07. Epub 2008 Jan 28. Infect Immun. 2008. PMID: 18227167 Free PMC article.
-
Regulatory T cells and IL-10 independently counterregulate cytotoxic T lymphocyte responses induced by transcutaneous immunization.PLoS One. 2011;6(11):e27911. doi: 10.1371/journal.pone.0027911. Epub 2011 Nov 16. PLoS One. 2011. PMID: 22114725 Free PMC article.
-
Topical vaccination: the skin as a unique portal to adaptive immune responses.Semin Immunopathol. 2007 Apr;29(1):71-80. doi: 10.1007/s00281-007-0059-2. Semin Immunopathol. 2007. PMID: 17621956 Review.
-
Intranasal immunization with influenza antigens conjugated with cholera toxin subunit B stimulates broad spectrum immunity against influenza viruses.Hum Vaccin Immunother. 2014;10(5):1211-20. doi: 10.4161/hv.28407. Epub 2014 Mar 14. Hum Vaccin Immunother. 2014. PMID: 24632749 Free PMC article.
-
Epicutaneous immunization with type II collagen inhibits both onset and progression of chronic collagen-induced arthritis.PLoS One. 2007 Apr 18;2(4):e387. doi: 10.1371/journal.pone.0000387. PLoS One. 2007. PMID: 17440622 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical